Health Aff (Millwood). 2024 Aug;43(8):1159-1164. doi: 10.1377/hlthaff.2023.01215.
ABSTRACT
Among 196,766 commercially insured and Medicare Advantage patients who newly initiated biologic drugs with available biosimilar versions, biosimilar initiation increased from 1 percent in 2013 to 34 percent in 2022. Patients were less likely to initiate biosimilars if they were younger than age eighteen or the drug was prescribed by a specialist or administered in a hospital outpatient facility.
PMID:39102605 | DOI:10.1377/hlthaff.2023.01215
